Patents by Inventor Ana Martinez
Ana Martinez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150352082Abstract: The invention relates to a family of differently substituted benzothiazoles having inhibitory activity against casein kinase 1 (CK-1) enzyme, as a result of which they are suitable for use in the treatment or prevention of diseases caused by this enzyme, particularly diseases associated with circadian rhythm and inflammatory, autoimmune, psychiatric, neurodegenerative, neurological or ophthalmic diseases, as well as for inducing cell regenerationType: ApplicationFiled: December 12, 2013Publication date: December 10, 2015Applicant: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICASInventors: Ana MARTÍNEZ GIL, Daniel Ignacio PÉREZ FERNÁNDEZ, Carmen GIL AYUSO-GONTÁN, Irene GARCÍA SALADO, Miriam REDONDO SANCHO, Concepción PÉREZ MARTÍNEZ
-
Patent number: 9193688Abstract: The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.Type: GrantFiled: September 28, 2012Date of Patent: November 24, 2015Assignee: Consejo Superior de Investigaciones CientificasInventors: Ana Martinez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Concepcion Perez Martin, Daniel I. Perez Fernandez, Julio Alberto Reyes Rodriguez
-
Patent number: 9192610Abstract: The present invention relates to the use of a series of quinazoline-derived compounds to produce a medicament for the treatment and/or prevention of neurological and/or neurodegenerative diseases, such as Parkinson's disease or Alzheimer's disease. The present invention also relates to a method for the treatment and/prevention of neurological and/neurodegenerative diseases comprising the administration of a therapeutically effective amount of said compounds.Type: GrantFiled: May 20, 2010Date of Patent: November 24, 2015Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICASInventors: Ana Martínez Gil, Carmen Gil Ayuso-Gontan, Concepción Pérez Martín, Ana Pérez Castillo, José Morales García, Miriam Redondo Sancho, Marina Sanz San Cristóbal
-
Publication number: 20150057311Abstract: The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.Type: ApplicationFiled: September 28, 2012Publication date: February 26, 2015Applicant: Consejo Superior de Investigaciones Cientificas (CSIC)Inventors: Ana Martinez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Concepcion Perez Martin, Daniel I. Perez Fernandez, Julio Alberto Reyes Rodriguez
-
Patent number: 8686042Abstract: The invention relates to urea derivatives of formula (I) as inhibitors of glycogen synthase kinase 3?, GSK-3, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which GSK-3 is involved, such as Alzheimer's disease or non-insulin dependent diabetes mellitus.Type: GrantFiled: July 28, 2006Date of Patent: April 1, 2014Assignee: Neuropharma, S.A.Inventors: Ana Martinez Gil, Miguel Medina Padilla, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Ana Castro Morera, Ester Martin Aparicio
-
Publication number: 20140011835Abstract: The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or prophylaxis of a neurodegenerative or hematological disease or condition, their use as a medicament, especially for treating a neurodegenerative or hematological disease or condition, and a pharmaceutical composition comprising the compounds.Type: ApplicationFiled: September 15, 2013Publication date: January 9, 2014Applicant: Noscira, S.A.Inventors: Ana MARTINEZ GIL, Ana Castro Morera, Miguel Medina Padilla, Jorge Sanchez-Quesada, Mercedes Alonso Cascon, Laura Rubio Arrieta, Esther Garcia Palomero, Paola Usan Egea
-
Patent number: 8592446Abstract: The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition, their use as a medicament, especially for treating a treatment neurodegenerative or haematological disease or condition, and a pharmaceutical composition comprising the compounds.Type: GrantFiled: June 11, 2008Date of Patent: November 26, 2013Assignee: Noscira, S.A.Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Jorge Sanchez-Quesada, Mercedes Alonso Cascon, Laura Rubio Arrieta, Esther Garcia Palomero, Paola Usan Egea
-
Patent number: 8427359Abstract: Radar data associated with radar illumination of a movable target is processed to monitor motion of the target. A plurality of filter operations are performed in parallel on the radar data so that each filter operation produces target image information. The filter operations are defined to have respectively corresponding velocity ranges that differ from one another. The target image information produced by one of the filter operations represents the target more accurately than the target image information produced by the remainder of the filter operations when a current velocity of the target is within the velocity range associated with the one filter operation. In response to the current velocity of the target being within the velocity range associated with the one filter operation, motion of the target is tracked based on the target image information produced by the one filter operation.Type: GrantFiled: January 6, 2011Date of Patent: April 23, 2013Assignee: Sandia CorporationInventors: Douglas L. Bickel, David W. Harmony, Timothy P. Bielek, Jeff A. Hollowell, Margaret S. Murray, Ana Martinez
-
Publication number: 20120225879Abstract: The present invention is based on the use of a broad family of 5-imino-1,2,4-thiadiazoles as potential new drugs for the treatment of diseases in which PDE7 inhibition is important, specially inflammatory diseases, autoimmune and neurodegenerative disorders. On the other hand, compounds of the 5-imino-1,2,4-thiadiazole family are here described, as well as their synthetic procedures, and they may have great application as drug or drug candidates.Type: ApplicationFiled: October 4, 2010Publication date: September 6, 2012Applicant: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFACAS ( CSIC)Inventors: Ana Martínez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Daniel Perez Fernandez, Concepción Perez Martín, Ana María Perez Castillo, María Isabel Loza Garcia, María Isabe Cadavid Torres, José Brea Floriani
-
Publication number: 20120129877Abstract: The present invention relates to the use of a series of quinazoline-derived compounds to produce a medicament for the treatment and/or prevention of neurological and/or neurodegenerative diseases, such as Parkinson's disease or Alzheimer's disease. The present invention also relates to a method for the treatment and/prevention of neurological and/neurodegenerative diseases comprising the administration of a therapeutically effective amount of said compounds.Type: ApplicationFiled: May 20, 2010Publication date: May 24, 2012Applicant: Consejo Superior De Investigaciones CientificasInventors: Ana Martínez Gil, Carmen Gil Ayuso-Gontan, Concepción Pérez Martín, Ana Pérez Castillo, José Morales García, Miriam Redondo, Marina Sanz San Cristóbal
-
Patent number: 8158661Abstract: Provided are thiadiazolidine compounds of formula I wherein R1 is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.Type: GrantFiled: April 22, 2009Date of Patent: April 17, 2012Assignee: Noscira, S.A.Inventors: Miguel Medina Padilla, Mercedes Alonso Cascon, Isabel Dorronsoro Diaz, Ana Martinez Gil, Gema Panizo Del Pliego, Ana Fuertes Huerta, Maria Jose Perez Puerto
-
Patent number: 8067441Abstract: The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.Type: GrantFiled: July 28, 2006Date of Patent: November 29, 2011Assignees: Neuropharma, S.A., Instituto Biomar, S.A.Inventors: Ana Martinez Gil, Paola Usan Egea, Miguel Medina Padilla, Esther Garcia Palomero, Julia Perez Baz, Rosa Isabel Fernandez Chimeno, Antonio Medarde Fernandez, Librada Maria Canedo Hernandez, Francisco Romero Millan, Ana Castro Morera, Mercedes Alonso Cascon, Jorge Sanchez Quesada
-
N-(2-THIAZOLYL)-AMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY, DIABETES AND CARDIOVASCULAR DISEASES
Publication number: 20110213000Abstract: The invention relates to the use of a compound of formula (I): its pharmaceutically acceptable salts, prodrugs and/or solvates, in the preparation of a medicinal product for the treatment of a disease presenting altered adiponectin levels or in which it is necessary to alter the adiponectin protein levels.Type: ApplicationFiled: August 1, 2008Publication date: September 1, 2011Applicant: ZELTIA, S.A.Inventors: Ana Martínez Gil, Mercedes Alonso Cascón, Gema Santamaría Núñez, Marta Martínez Díez, Javier López Ogalla -
Publication number: 20110144148Abstract: The invention provides compounds of formula: which have a tacrine moiety connected to an heterocyclic moiety through a linker. Through careful selection of the substituents and the linker, the activity and selectivity towards acetylcholinesterase can be modulated. The compounds show potent AChE inhibition activities together with modifications in the ?-amyloid aggregation properties by binding simultaneously to the catalytic and peripheral AChE sites. They are useful in the treatment of AChE mediated diseases, such as the Alzheimer's disease.Type: ApplicationFiled: February 18, 2011Publication date: June 16, 2011Applicant: NOSCIRA, S.A.Inventors: Ana Martinez Gil, Isabel Dorronsoro Diaz, Laura Rubio Arrieta, Diana Alonso Gordillo, Ana Fuertes Huerta, Susana Morales-Alcelay, Maria Del Monte Millan, Esther Garcia Palomero, Paola Usan Egea, Celia De Austria, Miguel Medina Padilla, Pilar Munoz Ruiz
-
Publication number: 20110092591Abstract: The present invention is related to a family of phenyl-prenyl derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the compounds of formula (I) for medical use, particularly for the use for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder, and to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.Type: ApplicationFiled: February 6, 2009Publication date: April 21, 2011Applicant: NOSCIRA S.A.Inventors: Javier Lopez Ogalla, Pilar Munoz Ruiz, Diana Alonso Gordillo, Miguel Medina Padilla, Esther Garcia Palomero, Ana Martinez Gil, Ana Castro Morera
-
Patent number: 7910739Abstract: The invention provides compounds of formula: which have a tacrine moiety connected to an heterocyclic moiety through a linker. Through careful selection of the substituents and the linker, the activity and selectivity towards acetylcholinesterase can be modulated. The compounds show potent AChE inhibition activities together with modifications in the ?-amyloid aggregation properties by binding simultaneously to the catalytic and peripheral AChE sites. They are useful in the treatment of AChE mediated diseases, such as the Alzheimer's disease.Type: GrantFiled: July 9, 2004Date of Patent: March 22, 2011Assignee: Noscira, S.A.Inventors: Ana Martinez Gil, Isabel Dorronsoro Diaz, Laura Rubio Arrieta, Diana Alonso Gordillo, Ana Fuertes Huerta, Susana Morales-Alcelay, Maria Del Monte Millan, Esther Garcia Palomero, Paola Usan Egea, Celia De Austria, Miguel Medina Padilla, Pilar Munoz Ruiz
-
Publication number: 20100304384Abstract: The present invention generally relates to a method for the identification of compounds for the treatment of neurodegenerative diseases. Said method is based on a cell model for neurodegeneration useful for the identification of potentially useful compounds for the treatment or the prevention of a neurodegenerative disease associated with deficient expression of the DDIT3 gene, also known as CHOP.Type: ApplicationFiled: November 13, 2008Publication date: December 2, 2010Applicant: UNIVERSIDAD AUTONOMA DE MADRIDInventors: Fernando Valdivieso Ámate, Maria Jesús Bullido Gómez-Heras, Ana Martínez García
-
Publication number: 20100267827Abstract: The present invention is related to a family of phenyl-prenyl-ether derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or 5 Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.Type: ApplicationFiled: August 1, 2007Publication date: October 21, 2010Applicant: NOSCIRA, S.A.Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Pilar Munoz Ruiz, Javier Lopez Ogalla, Laura Rubio Arrieta, Esther Garcia Palomero, Pablo Garcia Fernandez, Celia De Austria De Luque, Elena Delgado Hernandez, Paola Usan Egea, Rita Valenzuela Liminana, Jorge Sanchez-Quesada
-
Publication number: 20100240692Abstract: The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition, their use as a medicament, especially for treating a treatment neurodegenerative or haematological disease or condition, and a pharmaceutical composition comprising the compounds.Type: ApplicationFiled: June 11, 2008Publication date: September 23, 2010Applicant: NOSCIRA, S.A.Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Jorge Sanchez-Quesada, Mercedes Alonso Cascon, Laura Rubio Arrieta, Esther Garcia Palomero, Paola Usan Egea
-
Patent number: 7781463Abstract: Compounds of general formula (I): where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.Type: GrantFiled: April 20, 2007Date of Patent: August 24, 2010Assignees: Consejo Superior de Investigaciones Cientificas, Universidad Autonoma de Madrid (UAM)Inventors: Ana Martinez Gil, Ana Castro Morera, Maria Concepcion Martin Perez, Mercedes Alonso Cascon, Isabel Dorronsoro Diaz, Francisco Jose Moreno Munoz, Francisco Wandosell Jurado